Zobrazeno 1 - 10
of 213
pro vyhledávání: '"Harald Hofer"'
Autor:
Carolin Cornelius, Katrin Schöneweis, Fanny Georgi, Milena Weber, Verena Niederberger, Petra Zieglmayer, Katarzyna Niespodziana, Michael Trauner, Harald Hofer, Stephan Urban, Rudolf Valenta
Publikováno v:
EBioMedicine, Vol 11, Iss C, Pp 58-67 (2016)
Background: We have constructed and clinically evaluated a hypoallergenic vaccine for grass pollen allergy, BM32, which is based on fusion proteins consisting of peptides from the IgE binding sites of the major grass pollen allergens fused to preS (p
Externí odkaz:
https://doaj.org/article/fcc8a1eac2a04fd6b4b45b4135bf769c
Autor:
Robert Strassl, Karoline Rutter, Albert Friedrich Stättermayer, Sandra Beinhardt, Michael Kammer, Harald Hofer, Peter Ferenci, Theresia Popow-Kraupp
Publikováno v:
PLoS ONE, Vol 10, Iss 8, p e0135963 (2015)
BACKGROUND AND AIMS:Monitoring of chronic Hepatitis C (CHC) treatment relies on HCV RNA quantification by means of real-time PCR methods. Assay specific analytical sensitivities may impact therapy management. METHODS:Comparative analysis between thre
Externí odkaz:
https://doaj.org/article/312052f44b30449a81f7c8739e93a078
Autor:
Eva Rath, Michael Bonelli, Christina Duftner, Johann Gruber, Peter Mandl, Florentine Moazedi-Furst, Herwig Pieringer, Rudolf Puchner, Holger Flick, Helmut J. F. Salzer, Günter Weiss, Stefan Winkler, Hans Skvara, Alexander Moschen, Harald Hofer, Julia Feurstein, Judith Sautner
Publikováno v:
Zeitschrift für Rheumatologie. 82:163-174
ZusammenfassungIn diesem österreichweiten Consensus Statement sind die Empfehlungen zum Umgang mit latenter Tuberkulose bei Therapie mit biologischen und „targeted synthetic“ DMARDs zusammengefasst. Die wesentlichen Fragen bezüglich des Screeni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd8d2bb9ff812ced0646ffb57ba457b4
https://doi.org/10.1007/s00393-022-01274-6
https://doi.org/10.1007/s00393-022-01274-6
Autor:
Eva Rath, Michael Bonelli, Christina Duftner, Johann Gruber, Peter Mandl, Florentine Moazedi-Furst, Herwig Pieringer, Rudolf Puchner, Holger Flick, Helmut J. F. Salzer, Günter Weiss, Stefan Winkler, Hans Skvara, Alexander Moschen, Harald Hofer, Julia Feurstein, Judith Sautner
Publikováno v:
Wiener klinische Wochenschrift. 134:751-765
SummaryThis publication provides a thorough analysis of the most relevant topics concerning the management of latent tuberculosis when using biologic and targeted synthetic Disease Modifying Antirheumatic Drugs (DMARDs) by a multidisciplinary, select
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d24b02f79aa4def1d7a2e8472b206a07
https://doi.org/10.1007/s00508-022-02062-7
https://doi.org/10.1007/s00508-022-02062-7
Autor:
Tuul Purevsambuu, Simona Bota, Florian Hucke, Harald Hofer, Peter Ferenci, Wolfgang Sieghart, Markus Peck‐Radosavljevic
Publikováno v:
Liver Cancer International. 3:53-62
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac80f35bc5bd711658469b6a0e744f89
https://doi.org/10.1002/lci2.52
https://doi.org/10.1002/lci2.52
Autor:
Eva, Rath, Michael, Bonelli, Christina, Duftner, Johann, Gruber, Peter, Mandl, Florentine, Moazedi-Furst, Herwig, Pieringer, Rudolf, Puchner, Holger, Flick, Helmut J F, Salzer, Günter, Weiss, Stefan, Winkler, Hans, Skvara, Alexander, Moschen, Harald, Hofer, Julia, Feurstein, Judith, Sautner
Publikováno v:
Zeitschrift fur RheumatologieLiteratur.
This nationwide Austrian consensus statement summarizes the recommendations on the management of latent tuberculosis by treatment with biologic and targeted synthetic DMARDs. The essential questions with respect to screening and preventive treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b8078fdedd5c7eee2555b29527142ee0
https://pubmed.ncbi.nlm.nih.gov/36342525
https://pubmed.ncbi.nlm.nih.gov/36342525
Publikováno v:
Journal für Gastroenterologische und Hepatologische Erkrankungen. 19:34-43
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c502815b8f1ca609eb64da17fd74dffd
https://doi.org/10.1007/s41971-021-00100-1
https://doi.org/10.1007/s41971-021-00100-1
Autor:
Christian Datz, Heinz Zoller, Thomas Reiberger, Markus Peck-Radosavljevic, Vanessa Stadlbauer-Köllner, Harald Hofer, Andreas Maieron, Albert Friedrich Stättermayer, Stephanie Hametner-Schreil, Thomas Stulnig, Peter Fickert, Michael Gschwantler, Elmar Aigner
Publikováno v:
Journal für Gastroenterologische und Hepatologische Erkrankungen. 19:44-53
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2eb3c359fb18d68bb55f50a57f488faa
https://doi.org/10.1007/s41971-021-00095-9
https://doi.org/10.1007/s41971-021-00095-9
Autor:
Zhenzhen Zhang, Yves Horsmans, Francesco Negro, Nasser Semmo, Fiona Marra, Carlos Roncero, Nuno Marques, Michael Gschwantler, Włodzimierz Mazur, Rawi Hazzan, Mark Bondin, Georges Philippe Pageaux, Robert Flisiak, Konstantinos Mimidis, Tarik Asselah, Harald Hofer, Suzanne Bourgeois, John Marcinak, Pietro Lampertico, Alessio Aghemo, Ella Veitsman, Ioannis Goulis
Publikováno v:
Aghemo, Alessio; Horsmans, Yves; Bourgeois, Stefan; Bondin, Mark; Gschwantler, Michael; Hofer, Harald; Semmo, Nasser; Negro, Francesco; Zhang, Zhenzhen; Marcinak, John; Veitsman, Ella; Hazzan, Rawi; Mimidis, Konstantinos; Goulis, Ioannis; Marques, Nuno; Flisiak, Robert; Mazur, Wlodzimierz; Roncero, Carlos; Marra, Fiona; Pageaux, Georges Philippe; ... (2021). Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir. Infectious diseases and therapy, 10(4), pp. 2203-2222. Springer 10.1007/s40121-021-00455-1
Infectious diseases and therapy, Vol. 10, no.4, p. 2203-2222 (2021)
Infectious Diseases and Therapy
Infectious Diseases and Therapy (2021)
Infectious diseases and therapy, Vol. 10, no.4, p. 2203-2222 (2021)
Infectious Diseases and Therapy
Infectious Diseases and Therapy (2021)
Introduction Glecaprevir/pibrentasvir is approved for treating chronic hepatitis C virus (HCV) genotypes (GT) 1–6. We evaluated real-world effectiveness, safety, and patient-reported outcomes of glecaprevir/pibrentasvir in underserved patient popul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97bff272ab6e3dd79841032716fb8d2a
https://doi.org/10.1007/s40121-021-00455-1
https://doi.org/10.1007/s40121-021-00455-1
Autor:
P Munda, Harald Hofer, Karl Kashofer, Emina Halilbasic, Tatjana Stojakovic, Martin Krššák, Stefan Traussnigg, Günter Fauler, Michael Trauner, Michael Wolzt
Publikováno v:
Wiener Klinische Wochenschrift
Summary Background The PX-104 is an oral non-steroidal agonist for the farnesoid X receptor (FXR), a key regulator of bile acid (BA), glucose and lipid homeostasis. Aims and methods This single center, proof of concept study evaluated the efficacy, s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c6c090ee33409137be5d019e42ce3f8
https://doi.org/10.1007/s00508-020-01735-5
https://doi.org/10.1007/s00508-020-01735-5